Now, while talking at the Humans to Mars summit, Musk has warned that establishing a human colony on Mars will be very challenging, and it may even result in the deaths of Earthlings on the Red Planet.

Musk, during his talk, revealed that the journey to Mars will not be a hard task, but setting up a self-sustained colony will be challenging. The SpaceX founder also warned that the upcoming manned mission to Mars is not designed for the faint-hearted, as there are chances for losing their lives during the trip.

“I want to emphasize that this is a very hard and dangerous difficult thing. Not for the faint of heart. Good chance you’ll die, it’s going to be tough going, but it will be pretty glorious if it works out,” said Musk, as quoted by CNBC.

Elon Musk has previously revealed that the future government which will be set up on Mars will be based on direct democracy. He also made it clear that all Martians will have a direct role in determining the decision-making process of the government. Musk is now planning to put a million people on Mars by 2050, but many skeptics consider this timeline an unrealistic one.

The post Is Elon Musk carrying out a suicidal Mars colonization mission? appeared first on The Gulf Indians.

“The first satellite will be launched in 2021 and the second – a technologically enhanced one – the following year,” said Dr. Khaled Al Hashmi, Director of the National Space Science and Technology Centre (NSSTC) at the UAE University in Al Ain. The NSSTC was jointly established by the university along with the UAE Space Agency and the Telecommunications Regulatory Authority (ICT-Fund).

Navigation satellites offer positioning signals for navigation functions in car navigation systems and smartphones. They use signals from satellites for satellite positioning services to help detect someone’s current location. These services are also used for surveying and disaster prevention.

The navigation satellite will be the first project of Satellite Assembly, Integration and Testing (AIT) Centre, a collaboration formed by Tawazun Economic Council with Airbus and the NSSTC. The satellite project is funded by the UAE Space Agency.

The new satellite is not aimed at replacing any existing Global Navigation Satellite Systems (GNSS) but can be used as a substitute if one existing system does not work, he clarified. It can also be used for purposes such as deploying drones.

Right now, there are four GNSS – Global Positioning System (GPS) of the United States, GLONASS of Russia, Galileo of the European Union and BeiDou of China. There are also two regional systems – the Quasi-Zenith Satellite System (QZSS), of Japan and the Indian Regional Navigation Satellite System (IRNSS), later given the operational name Navigation with Indian Constellation or NavIC.
The UAE’s Mars Mission, Hope Probe, contributed to the establishment of the AIT Centre, the official said.
The second project of the AIT Centre is the development of 813, the Arab Satellite, an initiative announced by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice-President, Prime Minister and Ruler of Dubai.

The first phase called the mission concept is complete, Al Hashmi said. The team will soon move to the second phase and has constituted a local team; next task is selecting partners from other Arab countries participating in the project, he revealed.
The UAE initiated the creation of the first Arab Space Coordination Group in 2019 along with 10 Arab nations to develop 813, an advanced satellite funded by the UAE Space Agency to monitor earth, environment and climate. The name 813 refers to the date that marked the beginning of prosperity for the House of Wisdom in Baghdad under the reign of Al-Ma’mun.

The new satellite will be designed and manufactured by Arab engineers from countries that have signed the charter for the launch. The 11 countries are the UAE, Jordan, Bahrain, Algeria, Saudi Arabia, Sudan, Lebanon, Kuwait, Morocco and Egypt. The member countries voted for the UAE to lead the new organisation.

The satellite that will be launched in 2024 will be the first in the region to collect atmospheric data on climate change. The collected data will be shared with other universities and institutions in the Arab world, he explained.

Meanwhile, the Hope Probe, which took off from Japan’s Tanegashima Space Centre on July 20, is staying healthy on its course and the Mohammed Bin Rashid Space Centre in Dubai is receiving signals as per the expectations, the official revealed.

Space missions will raise hopes about future of science and technology in the county and region, Al Hashmi said.

The post UAE to launch navigation satellite appeared first on The Gulf Indians.

Sheikh Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health, Abu Dhabi, was the first individual in the world to commence the trial of a Phase III inactivated vaccine for COVID-19. Acting Undersecretary of the Department Dr. Jamal Al Kaabi was the second volunteer to try the vaccine showcasing the commitment of the UAE Government and the Health Authorities to find a cure for humanity’s biggest challenge of the 21st century.

The world’s first Phase III trial is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare, currently at the forefront of the battle against COVID-19 in the UAE, and Sinopharm CNBG, the world’s sixth largest vaccine manufacturer, ranked 169th on the Fortune Global 500 list of 2018.

The trials are being operated by health practitioners from Abu Dhabi Health Services, SEHA, who are providing facilities at five of their clinics in Abu Dhabi and Al Ain in addition to a mobile clinic to ensure the trials are readily accessible to volunteers participating in the programme.

Over the past few months, G42 Healthcare meanwhile, has established a massive throughput laboratory to speed up the detection of the disease; manufactured essential Personal Protective Equipment; conducted research into new vaccines and drug therapies, and used its advanced AI capabilities to map and predict trends in the outbreak, virus mutations and help combat the disease.

The UAE was the preferred choice for the cooperation partnership to conduct the Phase III trials for the inactive vaccine as the nation is home to over 200 nationalities, allowing for robust research across multiple ethnicities and increasing its feasibility for global application on the success of the trials.

The UAE Health Authorities have recently issued a permit for up to 15,000 volunteers to take part in the trials. G42 Healthcare and SEHA are working towards achieving a minimum of 5,000 participants in the first stage of the programme to ensure the robustness of the results.

Today’s clinical trial commencement is the start of a series of national initiatives to both foster population health and to enhance the UAE’s medical research and development capabilities, including the local capacity to manufacture the vaccine.

Trial formally began in the presence of Chinese Ambassador to the UAE Ni Jian; senior health department officials and G42 Healthcare and Sinopharm CNBG representatives. The first group of volunteers including UAE nationals and expatriates received the vaccine at Sheikh Khalifa Medical City.

The clinical trials are being conducted under the strict guidance and supervision of the Department of Health Abu Dhabi and SEHA – the Abu Dhabi Health Services Company. The trials follow all international guidelines stipulated by the WHO and the United States Food and Drug Administration, FDA.

The study, if successful, will be approved and accredited by the Ethics Committee for Scientific Research in the Emirate of Abu Dhabi.

Commenting on the start of the programme, Dr. Nawal Ahmed Alkaabi, UAE Principle Investigator Sheikh Khalifa Medical City CMO, and Chairperson of the National COVID-19 Clinical Management Committee, said, “Our participation in this trial enables us to make a major contribution in the global fight to combat the COVID-19 pandemic. It is a matter of national pride that we are able to help facilitate the trial process that could have a worldwide impact and help people around the world to benefit from research and – if successful – the manufacture of a vaccine to fight back against this disease.”

The phase III clinical trial follows the success of the phase I and phase II trials conducted by Sinopharm in China, which resulted in 100 percent of the volunteers generating antibodies after two doses in 28 days. The phase III trials will be open to individual volunteers aged between 18 and 60 living in Abu Dhabi and Al Ain and will last for 42 days.

A key factor for COVID-19 vaccine is the urgency around global implementation. Computing power, data processing and diagnostic analysis are G42 Healthcare’s global competitive advantage to support the successful delivery of the world’s first phase III trials of inactivated vaccine.

G42 Healthcare CEO Ashish Koshy said, “We are enormously proud that Sinopharm CNBG has partnered G42 Healthcare in this groundbreaking phase III clinical trial in the UAE. Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, G42 Healthcare is uniquely postured to conduct these trials. G42 Healthcare will be responsible for running clinical operations for this trial. We will be leveraging our group’s technical and our own business capabilities to compute, correlate and provide fast and synthesized insights by deploying multiple AI models on the data generated during the trials to accelerate the much awaiting results.

“G42 Healthcare will be mobilizing the logistical management of the trials taking in learnings from its proven capabilities in CRO management, clinical sites initiations and other E2E programme management activities.”

Jingjin Zhu, President, Biological products, Sinopharm CNBG added, “The United Arab Emirates is a nation of innovation and tolerance, that is home to individuals from every part of the world and ethnic background. We will work closely with our partner to complete this clinical trials successfully, and make this vaccine available to the people in need worldwide. With the full support of local authorities, cutting-edge technologies provided by our partner G42 Healthcare, and high-quality services and supports from the medical and clinical entities, we will jointly contribute to the battle against COVID-19 worldwide.”

Now that the trials have officially commenced, G42 Healthcare and the UAE Health Authorities will shortly launch a public awareness campaign to encourage UAE residents to participate in this critical to humanity clinical trial programme.

The post World’s first phase III clinical trial of COVID-19 inactivated vaccine begins in UAE appeared first on The Gulf Indians.